November 14, 2023
Clinical Lab Products
Digital Morphology Solution Predicts Breast Cancer Recurrence
Focused on Changing Breast Cancer Outcomes
PreciseDx® is dedicated to supporting more personalized and precise treatments for breast cancer.
On average, every two minutes a woman is diagnosed with breast cancer in the United States.
About 1 in 8 U.S. women (about 2.3 million diagnosed annually) will develop invasive breast cancer over the course of their lifetime.
About PreciseDx
PreciseDx® is the only Cancer Risk Stratification company to provide patient-specific risk information through the analysis of morphology features, enabling better and more personalized treatment and outcomes. Clinical teams can rely on PreciseDx for unmatched insights and actionable intelligence in determining the best treatment for each patient.
Integrating artificial intelligence, lab processes and workflow systems
Transforming clinical modeling, patient phenotyping, and image analysis
Providing unmatched insights to support pathologists, and oncologists
Better Data. Better Outcomes.
PreciseDx’s AI-powered predictive platform creates disease-specific assays that deliver new levels of patient risk information to drive benefits across the healthcare continuum.
- Patients
- Providers
- Payers
- BioPharma
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Patients
The PreciseDx platform enables individualized treatment plans and supports improved patient outcomes.
Providers
For providers, PreciseDx delivers highly accurate risk profiles, enables diagnostic precision, reduces error rates and decreases costs.
Payers
By providing accurate risk profiles for each individual patient, PreciseDx enables decreased costs for payers.
BioPharma
The PreciseDx AI platform is available for biopharmaceutical research and development, enabling researchers to leverage AI insights and data derived from high-volume, well-annotated study populations.
Corporate Council Member of
The National Comprehensive Cancer Network® (NCCN®)
Jack Zeineh, PreciseDx
Corporate Council Member of
The National Comprehensive Cancer Network® (NCCN®)
Featured Resources & Media
Media Coverage
Publication
November 3, 2023
Clinical Breast Cancer
PreciseDx’s “Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer” Featured in Clinical Breast Cancer
Infographic
Media Coverage
September 19, 2023
Forbes
Embracing A Human-AI Partnership To Harness The Power Of Healthcare Innovation
Media Coverage
Media Coverage
August 22, 2023
Precision Medicine Online's Risk Stratification Section
PreciseDx Begins Limited Rollout of ‘Quantitative’ Test for Grading Invasive Breast Cancer
Media Coverage
November 14, 2023
Clinical Lab Products
Digital Morphology Solution Predicts Breast Cancer Recurrence
Publication
November 3, 2023
Clinical Breast Cancer
PreciseDx’s “Analytical Validation of a Digital Breast Cancer Test Predicting Recurrence in Early-Stage Breast Cancer” Featured in Clinical Breast Cancer
Infographic